Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. [electronic resource]
Producer: 20180605Description: e508-e514 p. digitalISSN:- 1878-8769
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab -- administration & dosage
- Brain Neoplasms -- drug therapy
- Carmustine -- administration & dosage
- Combined Modality Therapy
- Cranial Irradiation -- adverse effects
- Craniotomy
- Cysts -- etiology
- Dacarbazine -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Drug Evaluation
- Drug Implants
- Drug Synergism
- Female
- Follow-Up Studies
- Glioblastoma -- drug therapy
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- surgery
- Neurosurgical Procedures
- Postoperative Hemorrhage -- etiology
- Proportional Hazards Models
- Retrospective Studies
- Temozolomide
- Treatment Outcome
- Tumor Microenvironment
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.